The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Abdullaeva N.M.

Russian Medical Academy of Continuous Professional Education

A sad addition

Authors:

Abdullaeva N.M.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(10): 28‑32

Read: 189 times

Buy for 300₽
Contact the author
Table of contents

To cite this article:

Abdullaeva NM. A sad addition. Non Nocere. New Therapeutic Journal. 2025;(10):28‑32. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Extrapulmonary manifestations of COPD. Depression.

Authors:

Abdullaeva N.M.

Russian Medical Academy of Continuous Professional Education

Close metadata

References:

  1. Kanner RE, Morris AH. Clinical and psychological findings of patients with chronic obstructive pulmonary disease. Annals of Internal Medicine. 1976;85(4):447-452. 
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Prevention, Diagnosis and Management of COPD: 2023 Report (Date of Access: 14.09.2025). https://goldcopd.org/2023-gold-report-2/
  3. Qin P, Hawton K, Mortensen PB, Webb R. Combined effects of physical illness and comorbid psychiatric disorder on risk of suicide in a national population study. Br J Psychiatry. 2014 Jun;204(6):430-435.  https://doi.org/10.1192/bjp.bp.113.128785
  4. Dalal AA, et al. Impact of depression on hospitalizations and emergency department use for patients with asthma and chronic obstructive pulmonary disease. Am J Manag Care. 2011;17(8): e298-e306.
  5. Lu Y, et al. The impact of depression and anxiety on mortality in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Affect Disord. 2017;210:188-196. 
  6. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. Journal of Clinical Psychiatry. 2005;66: Suppl 7:5-13. 
  7. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax. 1999 Aug;54(8):688-692.  https://doi.org/10.1136/thx.54.8.688
  8. Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013 Sep;144(3):766-777.  https://doi.org/10.1378/chest.12-1911
  9. Zhang MWB, et al. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respirology. 2021;26(9): 817-833. 
  10. Dantzer R. Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiol Rev. 2018 Jan 1;98(1):477-504.  https://doi.org/10.1152/physrev.00039.2016
  11. Schmaal L, Hibar DP, Sämann PG, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry. 2017 Jun;22(6):900-909.  https://doi.org/10.1038/mp.2016.60
  12. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016 Jan;16(1):22-34.  https://doi.org/10.1038/nri.2015.5
  13. Janssens T, De Peuter S, Stans L, et al. Dyspnea perception in COPD: association between anxiety, dyspnea-related fear, and dyspnea in a pulmonary rehabilitation program. Chest. 2011 Sep;140(3):618-625.  https://doi.org/10.1378/chest.10-3257
  14. Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010 Dec;25(12):1209-1221. https://doi.org/10.1002/gps.2463
  15. Alexopoulos GS. Depression in the elderly. Lancet. 2005 Jun 4-10;365(9475):1961-1970. https://doi.org/10.1016/S0140-6736(05)66665-2
  16. Iyer AS, Bhatt SP, Garner JJ, et al. Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 Feb;13(2):197-203.  https://doi.org/10.1513/AnnalsATS.201507-439OC
  17. De Voogd JN, et al. Depressive symptoms as a covariate of health outcomes in patients with COPD. Respir Med. 2010;104(9):1403-1409 
  18. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Jul;30(4):183-192.  https://doi.org/10.1097/YIC.0000000000000078
  19. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb 23;2015(2): CD003793. https://doi.org/10.1002/14651858.CD003793.pub3
  20. Pollok J, van Agteren JE, Esterman AJ, Carson-Chahhoud KV. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 Mar 6;3(3):CD012347. https://doi.org/10.1002/14651858.CD012347.pub2
  21. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Prevention, Diagnosis and Management of COPD: 2024 Report (Date of Access: 07.09.2025). https://goldcopd.org/2024-gold-report/
  22. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015 Mar 7;385(9971):857-866.  https://doi.org/10.1016/S0140-6736(14)62410-7
  23. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-2303. https://doi.org/10.1016/S0140-6736(17)31191-1
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.